Kanai O - Search Results

1

Single-centre observational study of the safety and efficacy of thoracoscopy under local anaesthesia for the management of thoracic infections.

Fujita K, Saito Z, Ito T, Imakita T, Oi I, Kanai O, Yamamoto Y, Hata H, Sawai S, Tanizawa K. Fujita K, et al. Among authors: kanai o. BMC Res Notes. 2024 May 6;17(1):127. doi: 10.1186/s13104-024-06794-9. BMC Res Notes. 2024. PMID: 38705975 Free PMC article.

2

[A case of postoperative thymic carcinoma recurrence that was effectively treated with combination chemotherapy of nedaplatin and docetaxel].

Kataoka Y, Okamoto K, Kitamura T, Hayama M, Tanaka H, Kanai O, Kobayashi T, Okamura M, Inoue H, Oshio M, Motoishi M, Mio T, Sawai S, Hanaoka J. Kataoka Y, et al. Among authors: kanai o. Gan To Kagaku Ryoho. 2013 Dec;40(13):2561-3. Gan To Kagaku Ryoho. 2013. PMID: 24335370 Review. Japanese.

3

Repetitive responses to nanoparticle albumin-bound paclitaxel and carboplatin in malignant pleural mesothelioma.

Kanai O, Fujita K, Nakatani K, Mio T. Kanai O, et al. Respirol Case Rep. 2016 Jan 14;4(1):28-31. doi: 10.1002/rcr2.145. eCollection 2016 Mar. Respirol Case Rep. 2016. PMID: 26839699 Free PMC article.

4

Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.

Kanai O, Fujita K, Okamura M, Nakatani K, Mio T. Kanai O, et al. Ann Oncol. 2016 Jul;27(7):1354-6. doi: 10.1093/annonc/mdw148. Epub 2016 Mar 31. Ann Oncol. 2016. PMID: 27037297 Free article. No abstract available.

5

Small cell lung cancer transformation during immunotherapy with nivolumab: A case report.

Imakita T, Fujita K, Kanai O, Terashima T, Mio T. Imakita T, et al. Among authors: kanai o. Respir Med Case Rep. 2017 Mar 29;21:52-55. doi: 10.1016/j.rmcr.2017.03.019. eCollection 2017. Respir Med Case Rep. 2017. PMID: 28393006 Free PMC article.

6

Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance status.

Kanai O, Kim YH, Nakatani K, Fujita K, Mio T. Kanai O, et al. Clin Case Rep. 2017 Apr 26;5(6):927-930. doi: 10.1002/ccr3.973. eCollection 2017 Jun. Clin Case Rep. 2017. PMID: 28588841 Free PMC article.

7

Concurrence of nivolumab-induced interstitial lung disease and cancer invasion.

Kanai O, Nakatani K, Fujita K, Okamura M, Mio T. Kanai O, et al. Respirol Case Rep. 2017 Aug 11;5(6):e00257. doi: 10.1002/rcr2.257. eCollection 2017 Nov. Respirol Case Rep. 2017. PMID: 28811904 Free PMC article.

8

Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.

Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T. Fujita K, et al. Among authors: kanai o. Cancer Chemother Pharmacol. 2018 Jun;81(6):1105-1109. doi: 10.1007/s00280-018-3585-9. Epub 2018 Apr 19. Cancer Chemother Pharmacol. 2018. PMID: 29675747

9

Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.

Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Kanai O, et al. Among authors: kanai m. Thorac Cancer. 2018 Jul;9(7):847-855. doi: 10.1111/1759-7714.12759. Epub 2018 May 21. Thorac Cancer. 2018. PMID: 29782069 Free PMC article.

10

An implicit threat: dolutegravir-induced schizophrenic brief psychotic disorder and persistent cenesthopathy.

Kanai O, Fujita K, Mio T. Kanai O, et al. AIDS. 2018 Nov 28;32(18):2853-2854. doi: 10.1097/QAD.0000000000002029. AIDS. 2018. PMID: 30407255 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters